These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 21892857

  • 1. Trajectory analysis of healthcare costs for patients with major depressive disorder treated with high doses of duloxetine.
    Cui Z, Faries DE, Zhao Y, Novick D, Liu X.
    J Med Econ; 2011; 14(5):662-72. PubMed ID: 21892857
    [Abstract] [Full Text] [Related]

  • 2. Longitudinal analysis of healthcare costs: a case study of patients with major depressive disorder treated with duloxetine.
    Cui Z, Faries DE, Shen W, Able SL, Novick D.
    J Med Econ; 2013; 16(5):623-32. PubMed ID: 23425292
    [Abstract] [Full Text] [Related]

  • 3. Dosing patterns for duloxetine and predictors of high-dose prescriptions in patients with major depressive disorder: analysis from a United States third-party payer perspective.
    Liu X, Cui Z, Niu L, Faries DE, Ball T, Johnstone B.
    Clin Ther; 2011 Nov; 33(11):1726-38. PubMed ID: 22019345
    [Abstract] [Full Text] [Related]

  • 4. Early discontinuation and suboptimal dosing of duloxetine treatment in patients with major depressive disorder: analysis from a US third-party payer perspective.
    Cui Z, Faries DE, Gelwicks S, Novick D, Liu X.
    J Med Econ; 2012 Nov; 15(1):134-44. PubMed ID: 22014076
    [Abstract] [Full Text] [Related]

  • 5. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP.
    Depress Anxiety; 2007 Nov; 24(1):41-52. PubMed ID: 16845641
    [Abstract] [Full Text] [Related]

  • 6. Duloxetine compliance and its association with healthcare costs among patients with diabetic peripheral neuropathic pain.
    Wu N, Chen S, Boulanger L, Fraser K, Bledsoe SL, Zhao Y.
    J Med Econ; 2009 Sep; 12(3):192-202. PubMed ID: 19705975
    [Abstract] [Full Text] [Related]

  • 7. Medication adherence and healthcare costs among fibromyalgia patients treated with duloxetine.
    Zhao Y, Chen SY, Wu N, Fraser KA, Boulanger L.
    Pain Pract; 2011 Sep; 11(4):381-91. PubMed ID: 21199311
    [Abstract] [Full Text] [Related]

  • 8. Use of effect size to determine optimal dose of duloxetine in major depressive disorder.
    Pritchett YL, Marciniak MD, Corey-Lisle PK, Berzon RA, Desaiah D, Detke MJ.
    J Psychiatr Res; 2007 Sep; 41(3-4):311-8. PubMed ID: 16934840
    [Abstract] [Full Text] [Related]

  • 9. Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin.
    Zhao Y, Sun P, Watson P.
    Curr Med Res Opin; 2011 Apr; 27(4):785-92. PubMed ID: 21303196
    [Abstract] [Full Text] [Related]

  • 10. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
    Gaynor PJ, Gopal M, Zheng W, Martinez JM, Robinson MJ, Hann D, Marangell LB.
    Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410
    [Abstract] [Full Text] [Related]

  • 11. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D.
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [Abstract] [Full Text] [Related]

  • 12. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME.
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [Abstract] [Full Text] [Related]

  • 13. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [Abstract] [Full Text] [Related]

  • 14. Costs associated with attempted suicide among individuals with bipolar disorder.
    Stensland MD, Zhu B, Ascher-Svanum H, Ball DE.
    J Ment Health Policy Econ; 2010 Jun; 13(2):87-92. PubMed ID: 20919595
    [Abstract] [Full Text] [Related]

  • 15. Adherence and persistence with duloxetine and hospital utilization in patients with major depressive disorder.
    Liu X, Tepper PG, Able SL.
    Int Clin Psychopharmacol; 2011 May; 26(3):173-80. PubMed ID: 21278576
    [Abstract] [Full Text] [Related]

  • 16. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
    Gaynor PJ, Gopal M, Zheng W, Martinez JM, Robinson MJ, Marangell LB.
    Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411
    [Abstract] [Full Text] [Related]

  • 17. Direct medical costs and medication compliance among fibromyalgia patients: duloxetine initiators vs. pregabalin initiators.
    Sun P, Peng X, Sun S, Novick D, Faries DE, Andrews JS, Wohlreich MM, Wu A.
    Pain Pract; 2014 Jan; 14(1):22-31. PubMed ID: 23489659
    [Abstract] [Full Text] [Related]

  • 18. Comparative effectiveness in pain-related outcomes and health care utilizations between veterans with major depressive disorder treated with duloxetine and other antidepressants: a retrospective propensity score-matched comparison.
    Shi L, Liu J, Zhao Y.
    Pain Pract; 2012 Jun; 12(5):374-81. PubMed ID: 21951787
    [Abstract] [Full Text] [Related]

  • 19. Management of depression relapse: re-initiation of duloxetine treatment or dose increase.
    Fava M, Detke MJ, Balestrieri M, Wang F, Raskin J, Perahia D.
    J Psychiatr Res; 2006 Jun; 40(4):328-36. PubMed ID: 16678205
    [Abstract] [Full Text] [Related]

  • 20. Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases.
    Wang J, Liu X, Mullins CD.
    Curr Med Res Opin; 2011 Jul; 27(7):1303-13. PubMed ID: 21561393
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.